Sangamo is pioneering the future of genomic medicine
Sangamo Therapeutics is a genomic medicine company dedicated to translating groundbreaking science into medicines that transform the lives of patients and families afflicted with serious neurological disease. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from diseases for which today’s medicine can only offer symptom management at best.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
-
March 22, 2024
RICHMOND, Calif. --(BUSINESS WIRE)--Mar. 22, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of an aggregate of 24,761,905 shares
-
March 13, 2024
Data from novel proprietary neurotropic adeno-associated virus (AAV) delivery capsid, STAC-BBB, demonstrated industry-leading blood-brain barrier (BBB) penetration in non-human primates (NHPs) following intravenous administration, with capsid-enabled delivery of zinc finger payloads targeting prion
-
March 13, 2024
Novel AAV capsid engineered by Sangamo showed robust penetration of blood-brain barrier (BBB) and widespread transgene expression throughout brain in non-human primates (NHPs) following intravenous administration. Demonstrated industry-leading brain tropism and enrichment in NHPs, resulting in
-
March 12, 2024
RICHMOND, Calif. --(BUSINESS WIRE)--Mar. 12, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before the market opens on Wednesday, March 13, 2024 .
| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
View HTML | |
| PRE 14A | A preliminary proxy statement providing notification matters to be brought to a vote |
Proxy Filings
|
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 424B5 | Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3 |
Registration Statements
|
View HTML |
- More events are coming soon.
-
Mar 13, 2024 at 4:30 PM EDT
-
Feb 7, 2024 at 8:00 AM PST